
HROW Stock Forecast & Price Target
HROW Analyst Ratings
Bulls say
Harrow is also investing in developing their pipeline of new ophthalmic products, which could bring even more potential for future revenue growth.
Bears say
Harrow is facing headwinds in the industry due to seasonality and increased availability of High Deductible Health Plans (HDHP) leading to lower revenue in the first half of 2026 compared to the second half. Although the company has met its revenue guidance for 2026, they are heavily focused on acquiring new products and expanding their portfolio to stay competitive in the market. Despite potential incremental wins, there is uncertainty around their guidance for fourth quarter sales in 2027, making their stretch goal of $250M a potential challenge. Additionally, while investment in their products like VEVYE and IHEEZO may pay off in the long term, there is a risk of not seeing immediate increases in sales due to these products being in the early stages of growth.
This aggregate rating is based on analysts' research of Harrow Health Inc and is not a guaranteed prediction by Public.com or investment advice.
HROW Analyst Forecast & Price Prediction
Start investing in HROW
Order type
Buy in
Order amount
Est. shares
0 shares